Skip to main content

Table 1 Clinical characteristics of the study population (N = 218 patients)

From: Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

Initial diagnosis

 

Median age at BC diagnosis (years, range)

51 (24-81)

Invasive ductal carcinoma (patients, %)

202/218 (92.7%)

Median tumour size (mm, range)

25 mm (1-200)*

Presence of lymph node involvement (evaluable tumours, %)

72/134 evaluable tumours (53.7%)

Oestrogen receptor-positive (patients, %)

93/192* (48.4%)

Progesterone receptor-positive (patients, %)

60/164* (36.6%)

Treatments before CNS metastases

 

Chemotherapy before CNS metastases (patients, %)

210/218 (96.3%)

  HER2-targeted therapy before CNS metastases (patients, %)

197/218 (90.4%)

  Bevacizumab before CNS metastases (patients, %)

3/218 (1.4%)

  Hormone therapy before CNS metastases (patients, %) (ER and PR positive at initial diagnosis N = 110 patients)

82/110 (74.5%)

Local radiation therapy before CNS metastases (patients, %)

159/218 (72.9%)

Metastatic disease

 

Median time to first metastatic relapse, any site (months, range)

21.9 months (0-214.7)

Median time between initial BC diagnosis and CNS metastasis (months, range)

37.6 months (0-286.5)

Median time to first relapse and CNS metastasis (months, range)

12.9 months (0-283.7)

CNS metastasis at first relapse (patients, %)

39/217 (18%)

  Unique first site metastasis

31/217 (14.3%)

Carcinomatous meningitis

28/216 (13%)

CNS metastasis as secondary site (associated with other metastases)

167/218 (76.6%)

Other main metastatic sites at CNS metastasis diagnosis (n = 180)

 

  Bone

111/178 (62.4%)

  Lung/pleura

86/178 (48.3%)

  Lymph nodes

101/178 (56.7%)

  Liver

34/178 (19.1%)

Median interval between CNS metastasis and other metastases

5.5 months (0.1-29)

Survival following CNS metastasis

 

Median survival for study population (months, range)

13.1 months (11-15.8)

Median survival for CNS metastasis as first site of relapse

14.2 months (10.6-22.2)

Median survival for secondary CNS metastasis (associated with other metastases)

13 months (10.5-15.8)

Death at 2 years (Kaplan-Meier estimate)

70.27

Median time to GPA threshold 1-2/2.5-3/3.5-4 patients

 

  Score 1 - 2

10 months

  Score 2.5 - 3

12 months

  Score 3.5 - 4

24 months

  1. *Data was missing for some patients. BC: breast cancer; CNS: central nervous system; GPA: Graded Prognostic Assessment.